Welcome to our dedicated page for Tempus AI news (Ticker: TEM), a resource for investors and traders seeking the latest updates and insights on Tempus AI stock.
Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.
Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.
Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.
By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.
Northwestern Medicine and Tempus (NASDAQ: TEM) announced a collaboration to expand genomic testing access for Northwestern Medicine cancer patients, effective January 12, 2026.
The initiative aims to offer next-generation sequencing broadly across cancer types, including earlier-stage diagnoses, and to provide clinicians with DNA/RNA profiling, solid tissue testing, liquid biopsy, and minimal residual disease (MRD) assays. The partners expect the data to support more tailored treatments and to facilitate design of clinical trials for personalized cancer therapies.
Tempus (NASDAQ: TEM) reported a record Total Contract Value (TCV) >$1.1 billion as of December 31, 2025 and preliminary, unaudited Data and applications revenue of approximately $316 million for full-year 2025, about 31% year-over-year growth. Insights (data licensing) grew 38% and 2025 net revenue retention was approximately 126%. Tempus signed data agreements with more than 70 customers, including several large pharma companies. The results are preliminary and unaudited; Tempus expects to report complete fourth-quarter and full-year 2025 audited results on its February 2026 earnings call and notes final figures may differ materially from these estimates.
Tempus (NASDAQ: TEM) reported preliminary, unaudited results for Q4 and full-year 2025 showing strong growth. Full-year 2025 revenue was approximately $1.27 billion (+~83% YoY) with ~30% organic growth (excluding Ambry). Diagnostics revenue was ~$955 million (+~111% YoY) and Data & Applications revenue was ~$316 million (+~31% YoY). Q4 2025 revenue was ~$367 million (+~83% YoY) with Q4 Data & Applications at ~$100 million. Results are preliminary, unaudited, and subject to change; full results expected on the February 2026 earnings call.
Tempus (NASDAQ: TEM) announced eight abstracts accepted for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium (Jan 8–10, San Francisco). Using Tempus Lens on de-identified clinical, genomic, and transcriptomic data, the studies report: subtype-specific DNA alterations in appendiceal neoplasms; CLDN1 expression linked to immune infiltration and improved survival with 1L chemo+IO in advanced biliary tract cancers; molecular/immune differences by age in enteropancreatic NETs; trends toward better survival with platinum in pancreatic cancers with non-BRCA/PALB2 DDR mutations (median rwOS 11.7 vs 9.8 months, p=0.471); PIN1 expression associations in PDAC; KRAS status and co-alteration profiles in resected pancreatic cancer; RAD51/GATA6 transcriptomic signatures predicting platinum benefit in BRCA/PALB2 wild-type mPC; and RTK amplifications present in ~10% of GI cancers with immunosuppressive TME features.
Tempus (NASDAQ:TEM) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026. Founder and CEO Eric Lefkofsky will deliver a presentation and live Q&A on January 12, 2026, 1:30–2:10 PM PST.
The presentation will be available via live webcast at the conference portal.
Tempus (NASDAQ: TEM) announced ten abstracts accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (Dec 9–12). The posters span multimodal AI analyses integrating genomic, transcriptomic, and real-world clinical data to refine risk stratification, characterize ESR1 and PIK3CA co-mutations (n=8,626), profile tumor immune microenvironments across subtypes and metastatic sites, assess biomarkers for trastuzumab deruxtecan response, and evaluate treatment sequencing and real-world outcomes in HR+/HER2- metastatic breast cancer.
Presentations highlight potential biomarkers, racial and male breast cancer insights, and implications for patient selection and therapy optimization.
Tempus (NASDAQ:TEM) will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 in New York City. Jim Rogers, Chief Financial Officer, will join a fireside chat at 10:30 AM ET. A live webcast will be available via the company’s Investor Relations events page.
Tempus (NASDAQ: TEM) launched a multi-year research study in collaboration with the Institute for Follicular Lymphoma Innovation (IFLI) to build a comprehensive, multi-omic dataset for follicular lymphoma (FL).
The study will enroll FL patients and apply next-generation sequencing, proteomics, and methylation analysis to integrate molecular profiling with real-world clinical data. The collaboration is Tempus’ first study partnership with a nonprofit foundation and aims to support biomarker discovery, whole-genome sequencing validation, and precision-medicine research.
FL represents roughly 10–20% of U.S. non-Hodgkin lymphoma cases; the release notes ~20% of patients progress within two years after chemoimmunotherapy and a 50% five-year overall survival, underscoring research needs.
Tempus (NASDAQ: TEM) announced six abstracts accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025, held November 5–9 in National Harbor, Maryland.
Key research includes: a multi-omic Immune Profile Score (IPS) predicting ICI outcomes in rare advanced solid cancers (n=90) and MSS colorectal cancer (n=46); a MAIT cell prevalence analysis across 190,189 patients; an automated TargetR multi-omics framework; an ultrahigh TMB ≥40 mut/MB analysis in 17,449 patients showing improved real-world response and survival; and AR alteration effects in 1,556 castration-resistant prostate cancer patients.
Summary not available.